Institut sur la nutrition et les aliments fonctionnels
Québec, G1V 0A6, Canada
NCT Number: NCT03754504
It is of major importance to refine prevention strategies in order to alleviate inflammation, insulin resistance and metabolic syndrome and it appear that improving gut health and microbiota represent a promising strategy. Cranberry-enriched diets may help prevent metabolic syndrome and its associated chronic diseases by a protective effect of gut health and microbiota. It is therefore highly relevant to test the hypothesis that a whole cranberry powder supplements (which include a mixture of polyphenols, free and fiber-associated proanthocyanidins, and fruits fibers) is associated with changes on the gut health and microbiota playing a major role in alleviating inflammation and obesity-associated metabolic disorders.
Looking for future studies?
Notify Me18 year–60 year
Male
Interventional
Not applicable
Québec, G1V 0A6, Canada
Over the past decade it has become clear that the gut microbiota is a key determinant of obesity and that its perturbations by nutritional insults play a significant role in the development of metabolic complications such as insulin resistance, type 2 diabetes, cardiovascular diseases and non-alcoholic fatty liver disease. Indeed, there is growing amounts of studies that have shown that dysbiosis of the intestinal microbiota promotes obesity-linked chronic inflammation, and is causally related to diet-induced type 2 diabetes. Our group recently published that a polyphenol-rich cranberry extract exert striking effect on the gut microbiota of high-fat and high-sucrose fed mice, which was associated with prevention of diet-induced weight gain, visceral obesity, insulin resistance and hepatic steatosis. Notably, metagenomic analyses of feces of the cranberry extract-treated mice suggested that these metabolic effects were associated with a dramatic increase in the proportion of Akkermansia muciniphila, a dominant commensal bacterium in the intestinal mucus layer which has received particular attention in the last few years since its abundance is associated with improved metabolic health and beneficial responses to various interventions in both mice and humans with obesity and diabetes. Polyphenols are now recognized as potent molecules capable to protect against obesity-linked metabolic diseases and dysbiosis. Among polyphenols, there is increasing evidence supporting the beneficial impact of dietary proanthocyanidins. Cranberries being rich in proanthocyanidins, we believe that these phyto-elements could be associated to their beneficial effects. On the other hand, apart from the recognized beneficial effects of fibers on gut health, their association with high molecular proanthocyanidins could also contribute to their health benefits.
The main objective of this study is to investigate in a cross-over randomized placebo-controlled clinical trial the beneficial properties of a whole cranberry powder on gut microbiota, intestinal health and metabolic syndrome parameters in overweight men.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
3 capsules /day of whole cranberry powder (500mg/each)
3 capsules/day of a placebo comparator
Time frame: At the beginning and the end of each treatment (4 weeks each)
Global variation of the fecal microbiota
Time frame: At the beginning and the end of each treatment (4 weeks each)
Plasma Lipopolysaccharides (LPS) and Lipopolysaccharide Binding Protein (LBP)
Time frame: At the beginning and the end of each treatment (4 weeks each)
Plasma zonulin
Time frame: At the beginning and the end of each treatment (4 weeks each)
Fecal calprotectin and chromogranin
Time frame: At the beginning and the end of each treatment (4 weeks each)
Measure short chain fatty acids in the feces
Time frame: At the beginning and the end of each treatment (4 weeks each)
Evaluation of gastrointestinal symptoms and stool consistency using standardized questionnaires
Time frame: At the beginning and the end of each treatment (4 weeks each)
Evaluation of plasma triglycerides (TG), Total cholesterol, LDL, HDL and Apolipoprotein B from the beginning to the end of two dietary treatment
Time frame: At the beginning and the end of each treatment (4 weeks each)
Evaluation of plasma high sensitive C-Reactive Protein (hs-CRP)
Time frame: At the beginning and the end of each treatment (4 weeks each)
Evaluation of plasma fasting glucose and insulin concentration
Laval University
Other
Evaluation of the Effect of Cranberry Whole Fruit Powder on Gut Microbiota Diversity, Intestinal Health and Metabolic Syndrome in Overweight Individuals: a Proof-of-concept Study
Acronym: MICA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04117802
Bacteremia, Body Weight
Québec, Canada
View Trial DetailsNCT04130321
Bacteremia, Body Weight
Québec, Canada
View Trial DetailsNCT02148653
Body Weight, Glucose Metabolism Disorders
Lund, Sweden
View Trial DetailsNCT05120661
Body Weight, Digestion
Wageningen, Gelderland, Netherlands
View Trial Details